Related Experiment Video

Updated: Jul 11, 2026

Generation of First Heart Field-like Cardiac Progenitors and Ventricular-like Cardiomyocytes from Human Pluripotent Stem Cells
08:37

Generation of First Heart Field-like Cardiac Progenitors and Ventricular-like Cardiomyocytes from Human Pluripotent Stem Cells

Published on: June 19, 2018

Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure

Tibor Kempf1, Stephan von Haehling, Timo Peter

  • 1Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.

Journal of the American College of Cardiology
|September 11, 2007
PubMed

Insights

Growth Differentiation Factor 15 (GDF-15) is a novel biomarker for predicting mortality risk in chronic heart failure (CHF) patients. Elevated GDF-15 levels provide crucial prognostic information beyond existing clinical and biochemical markers.

Area of Science:

  • Cardiology
  • Biomarkers
  • Heart Failure Research

Background:

  • Growth Differentiation Factor 15 (GDF-15) is a stress-responsive cytokine.
  • Elevated GDF-15 levels are observed in patients with chronic heart failure (CHF).
  • The prognostic value of GDF-15 in CHF and its relation to other biomarkers were previously unstudied.

Purpose of the Study:

  • To investigate the prognostic utility of GDF-15 in patients diagnosed with CHF.
  • To determine if GDF-15 predicts mortality in CHF patients.
  • To assess if GDF-15 offers additional prognostic information beyond established markers.

Main Methods:

  • Circulating GDF-15 levels were measured using immunoradiometric assay in 455 CHF patients.
  • Patients had a median left ventricular ejection fraction (LVEF) of 32%.
  • GDF-15 levels were correlated with clinical variables and other biomarkers.

Main Results:

  • Median GDF-15 levels were significantly elevated in CHF patients (1,949 ng/l).
  • GDF-15 levels correlated with NYHA functional class and NT-proBNP.
  • Mortality risk increased across GDF-15 quartiles, with GDF-15 independently predicting death after adjustments.

Conclusions:

  • GDF-15 is a novel biomarker for predicting mortality risk in CHF patients.
  • GDF-15 provides prognostic information beyond established clinical and biochemical markers.
  • GDF-15 offers added prognostic value to NYHA class, LVEF, and NT-proBNP.
Abstract

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...